Antibody drug conjugates (ADCs) are an important new modality that is showing great results in treating certain types of cancer. Manufacture of this drug class is complex insofar as it requires several GMP intermediates as inputs to the conjugation reaction to produce the drug substance. My team of technical consultants at Alira Health has a focus on biologics, and we do a lot of work with ADCs. I'm excited to announce publication of an article from my team entitled “Manufacturing challenges of therapeutic antibody-drug conjugates” by Dr. Peter Alexander and colleagues. The article appears as a featured report in the September 2023 issue of BioProcess International. Read the full article here: https://lnkd.in/gs_TyPe4
Steven Chamow’s Post
More Relevant Posts
-
Antibody drug conjugates (ADCs) are an important new modality that is showing great results in treating certain types of cancer. Manufacture of this drug class is complex insofar as it requires several GMP intermediates as inputs to the conjugation reaction to produce the drug substance. My team of technical consultants at Alira Health has a focus on biologics, and we do a lot of work with ADCs. I'm excited to announce publication of an article from my team entitled “Manufacturing challenges of therapeutic antibody-drug conjugates” by Dr. Peter Alexander and colleagues. The article appears as a featured report in the September 2023 issue of BioProcess International. Read the full article here: https://lnkd.in/gs_TyPe4
September 2023 - Featured Report
secure.viewer.zmags.com
-
This an excellent analysis.
Labs, Providers Strongly Oppose FDA LDT Proposed Rule in Public Comments
360dx.com
-
Roivant to Report Financial Results for the First Quarter
Roivant to Report Financial Results for the First Quarter
lifecarenews.in
-
Roivant to Report Financial Results for the First Quarter
Roivant to Report Financial Results for the First Quarter
lifecarenews.in
-
Roivant to Report Financial Results for the First Quarter
Roivant to Report Financial Results for the First Quarter
lifecarenews.in
-
Great data in the 60 page supplement.
Systematic Review of Cerebrospinal Fluid Biomarker Discovery in Neuro-Oncology: A Roadmap to Standardization and Clinical Application
ascopubs.org
-
Tomorrow, we will announce our financial results for the 3rd quarter of 2023. All details in a nutshell: ➡️ 7 a.m. (CET): Publication of our Q3 results ➡️ 9:30 a.m. (CET): Media conference call ➡️ 2 p.m. (CET): Conference call for analysts You can find further information here: https://lnkd.in/eRmPRD-g #EMDresults #Q3 #FinancialResults
Q3 2023 Results | Merck KGaA, Darmstadt, Germany
emdgroup.com
-
GSK's multiple myeloma drug BLENREP (Belantamab Mafodotin/Belamaf), once deemed a failure, is now showing promising potential following two significant trial victories. These pivotal results have reignited hopes within the company, with company projections suggesting that BLENREP could achieve peak sales exceeding USD 3 billion. Unlock the Power of Expert Insights and Thorough Analysis with DelveInsight Business Research LLP's European Hematology Association (EHA) 2024 Exclusive Coverage @ https://lnkd.in/gP5NZjUF #GSK #BLENREP #BelantamabMafodotin #Belamaf #multiplemyeloma #cancerdrug #clinicaltrials #pivotalresults #drugdevelopment #oncology #cancerresearch #treatmentsuccess #cancertreatment
BLENREP combo in DREAMM-7 study | EHA 2024
delveinsight.com
-
Immediate access to key insights derived from vast market data is crucial for achieving brand and portfolio success. Join this webinar to discover a unique partnership model that blends expertise, processes, and technology to scale that will accelerate market-readycommercial analytics. https://bit.ly/47UKgVa #CommercialAnalytics #Pharma #advancedanalytics #commercialsuccess
Accelerate access to market-ready commercial analytics
event.on24.com